BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 15779421)

  • 1. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reducing postprandial glucose levels. Glucosidase antagonists].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Nakamura J
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():457-61. PubMed ID: 15779422
    [No Abstract]   [Full Text] [Related]  

  • 5. [Characteristic of metformin for treatment of impaired glucose tolerance].
    Ishida W; Satoh J
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():433-7. PubMed ID: 15779418
    [No Abstract]   [Full Text] [Related]  

  • 6. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
    Nishimura R
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
    [No Abstract]   [Full Text] [Related]  

  • 7. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
    Welborn TA
    Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pathophysiological conditions progressing from impaired glucose tolerance: atherosclerosis].
    Yokote K; Saito Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():250-4. PubMed ID: 15779381
    [No Abstract]   [Full Text] [Related]  

  • 11. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
    Carlson RF
    Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
    Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
    Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
    Bischoff H
    Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.
    Hasegawa G; Kajiyama S; Tanaka T; Imai S; Kozai H; Fujinami A; Ohta M; Obayashi H; Park H; Nakano K; Tanaka M; Shiraishi E; Fukui M; Yoshikawa T; Nakamura N
    Clin Chim Acta; 2008 Apr; 390(1-2):110-4. PubMed ID: 18230353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analogues of amylin, alpha-glucosidase inhibitors and the digestive system in homeostasis regulation].
    Rybka J
    Vnitr Lek; 2011 Apr; 57(4):381-7. PubMed ID: 21612064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
    Yamada K
    Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alpha glucosidase inhibitor].
    Katsuta H; Ishida H
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():637-45. PubMed ID: 17458296
    [No Abstract]   [Full Text] [Related]  

  • 19. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
    Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.